Analysts think ETNB stock price could increase by 207%
Feb 21, 2025, 12:25 PM
-22.26%
What does ETNB do
89bio, a San Francisco-based biopharmaceutical company, focuses on therapies for liver and cardio-metabolic diseases, with its lead candidate, pegozafermin, targeting nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company went public on November 11, 2019, and employs 70 people.
11 analysts think ETNB stock price will increase by 207.12%. The current median analyst target is $33.66 compared to a current stock price of $10.96. The lowest analysts target is $12.12 and the highest analyst target is $51.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
